Spero Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
Spero Therapeutics, Inc. (SPRO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent of 0.00% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther · last filed 2025-03-27
- Spero Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2024 was 0.00%, a 100.00% decline from fiscal 2023.
- Spero Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2023 was 0.30%, a 70.00% decline from fiscal 2022.
- Spero Therapeutics, Inc. effective income tax rate reconciliation, nondeductible expense, other, percent for fiscal 2022 was 1.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent 12 month |
|---|---|
| 2024-12-31 | 0.00% 10-K · filed 2025-03-27 |
| 2023-12-31 | 0.30% 10-K · filed 2025-03-27 |
| 2022-12-31 | 1.00% 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |